We’re tackling the world’s most challenging diseases so that communities can thrive around the world
It is an affiliate of Medicines Development for Global Health (MDGH Australia), an independent biopharmaceutical company incorporated in Australia and registered as a charity with the Australian Charities and Not-for-Profits Commission.
MDGH’s mission is to address health inequity by putting new and improved medicines into the hands of people who need them most while its core expertise is in the development of medicines to rigorous regulatory standards.
The company was incorporated as a company limited by guarantee on 3 June 2015 and is now in the process of applying for registration as a charity with the UK Charities Commission. The sole member of the Company is MDGH Australia, and together have an active Collaboration Agreement to govern the relationship between the two entities.
Medicines Development for Global Health Limited is an independent biopharmaceutical company incorporated on 3 June 2015 as a company limited by guarantee in the UK. It is in the process of applying for registration as a charity with the Charity Commission for England and Wales.
Mark Sullivan is MDGH’s founder and managing director. He was previously a clinical programme head at GSK in London; Associate Director, Clinical at Gilead Sciences in California; and Chief Operating Officer of Australia’s vaccine design and development consortium at the University of New South Wales. He has contributed to three successful global registrational programs for HIV and hepatitis B therapeutics, has worked on 40 small molecule and biologic development programs at all stages, and led the development of moxidectin through FDA approval. Mark was the 2019 Victorian Australian of the Year, and in 2022 was awarded Officer of the Order of Australia in the Australia Day Honours List.
Chair of the Board
Kate has spent her career working to prove that global health is an investible asset class. Her work has focused on bridging the gap between commercial investment and development funding, including the management of the Global Health Investment Fund (GHIF) and establishing a financing strategy for the Coalition for Epidemic Preparedness Innovations (CEPI). Kate’s former clients include development agencies of the UK, Germany, Canada, Norway, Australia, and Netherlands; the World Bank; African Development Bank; private foundations including the Bill & Melinda Gates Foundation; and sovereigns in Africa and the Middle East. Kate is currently Chief Investment Officer at Univercells, working to create a new precedent for what it means to build mission-driven businesses in biotech. Prior to Univercells, Kate led healthcare initiatives at Lion’s Head Global Partners, an investment management and financial advisory firm focusing on frontier markets. Kate has lived and worked in the UK, US, Kenya, Nigeria, and South Africa. She holds a MA(Hons) in Philosophy, Politics and Economics from Magdalen College, Oxford University; a Master of Public Administration Dual Degree from the London School of Economics and Colombia University’s School of International and Public Affairs; and is a Chartered Financial Analyst.
Chair of the Board
Dr Michael Elliott, FRCP (London UK) has thirty years of pharmaceutical industry experience following six years in hospital medical practice. Currently he is Vice President, ACE (Australia, Canada, Europe) Medical Affairs, Gilead Sciences, London, UK and prior to this role was Vice President & Medical Director, GlaxoSmithKline Asia Pacific for 10 years. In the pharmaceutical industry, Michael has a wide range of global experience in medicine development, commercialization, governance, and strategy. He led global development programmes of early stage and late-stage compounds and has worked within the local operations divisions of a UK company (SB) and US companies (Schering-Plough, GSK) as well as within global R&D. For nine years, Michael has held his leadership role with Gilead Sciences during an accelerated growth phase which has included expansion and twelve launches of novel medicines in HIV, Viral Hepatitis and Haematology/Oncology. His six years of clinical practice included experience in Infectious Diseases, Cardiology, Chest Medicine and Diabetes/ Endocrinology. Michael is based in Sailsbury UK, has a diploma in Pharmaceutical Medicine UK, holds an MBA and is a graduate of the Australian Institute of Company Directors.
Lorna is currently Vice President, Commercial Operations, Asia Pacific of Seqirus bioCSL Ltd., (a CSL company). She has enjoyed a successful 25-year career in the pharmaceutical industry, encompassing clinical research, business development, marketing and sales across a wide variety of therapeutic areas, including respiratory, CNS, cardiopulmonary, oncology, metabolic, psychiatry, neurology, HIV, pain, and vaccines. Lorna previously worked for GSK Australia as Commercial Vice President, before establishing Ikaria Australia Pty Ltd., a biotherapeutics company that commercialised drugs and devices for intensive care medicine. She was a director and secretary of BioMelbourne Network (an industry-led membership association for organisations engaged in biotechnology, medical technology, and health innovation in the state of Victoria). Lorna graduated with a PhD in Neurobiology (University College London) and a BSc in Pharmacology (University of Glasgow), and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and the Royal Postgraduate Medical School (London).
Andrew Wilks is a serial entrepreneur with 25 years working in industry, following a highly successful academic career as a cancer researcher at the Ludwig Institute for Cancer Research. He went on to found Cytopia (1997), one of Australia’s earliest ASX-listed drug discovery companies. Since then, he has founded eleven companies in the drug discovery arena. He was co-founder of SYNthesis med chem, a global CRO with laboratories in China, and SYNthesis Research, a ‘venture-discovery’ company that funds and manages drug discovery collaborations generated from academia. Andrew holds an Adjunct Professorship at Monash University, and is an Honorary Enterprise Professor at the University of Melbourne. He is an elected Fellow of the Australian Academy of Technology and Engineering (ATSE) and of the Australian Academy of Health and Medical Sciences (AAHMS). He has received a number of awards including the JNJ AusBiotech Industry Leadership Award, the ATSE Clunies Ross Medal, and the Lackmann Award for Translational Research.
We are now generating the additional data required to carry out community-directed treatment in endemic areas, through targeting World Health Organization (WHO) endorsement for use in river blindness treatment programs.
Moxidectin is also being developed by MDGH Australia for other parasitic diseases that are caused by parasitic worm species or ectoparasites. These include programmes in scabies, strongyloidiasis, lymphatic filariasis and soil-transmitted helminths where human clinical trials are currently underway. Moxidectin for head lice is an additional development program at MDGH Australia, currently in the pre-clinical, proof-of-concept stage.
In 2019 and 2021, the European & Developing Countries Clinical Trials Partnership (EDCTP) provided two substantial grants to Medicines Development for Global Health Limited and partners: €4.6m for additional clinical trials comparing efficacy and safety of single or annual and biannual moxidectin or ivermectin treatment (grant RIA2017NCT-1843 MoxiMultiDoseMod), and €2.8m for the development of a paediatric formulation of moxidectin MiniMox (grant RIA2019PD-2880 MiniMox). Both projects are part of the EDCTP2 Programme supported by the European Union.
This project includes a paediatric dose-finding study, two phase 3b trials comparing efficacy and safety of single dose and annual and biannual doses of moxidectin or ivermectin treatment, and mathematical modelling of moxidectin and ivermectin based elimination strategies to support country policy decisions.
This project aims to develop and qualify a paediatric formulation of moxidectin suitable for children from one to three years of age, to determine an appropriate dose of the formulation for this age range and to assemble data for submission to the US FDA in support of adding the paediatric formulation to the US FDA prescribing information.
Website coming soon.
Amgen licenses AMG 634, an investigational treatment for tuberculosis and leprosy, to medicines development for global health...
Mark Sullivan, the founder, Managing Director and Board Member of Medicines Development for Global Health, was interviewed by Dr. Norman Swan on today’s Health Report, broadcast nationally in Australia. The interview covers MDGH’s business model, the FDA’s approval of Moxidectin, and the medicine’s potential to help the fight against river blindness, which is a leading global cause of preventable blindness. Click anywhere to listen to a recording on the ABC’s website.
Medicines Development is currently coordinating an international collaboration between Opal Therapeutics Inc. (Opal) and Massachusetts General Hospital (MGH) to develop a novel immunotherapy to treat HIV. The collaboration involves the Ragon Institute of MGH, MIT and Harvard, Oxford University and the St Stephen’s AIDS Trust (Chelsea and Westminster Hospital). The first in human clinical trial is currently being conducted in London Sponsored by Medicines Development.
Medicines Development for Global Health Limited
(Company number 09622645)
c/o BCS Windsor House,
Station Court, Station Road, Great Shelford,
CB22 6NE, United Kingdom
Medicines Development for Global Health Limited
ABN 7116 977 523, an Australian public company limited by guarantee registered under the Corporations Act 2001.
Level 1, 18 Kavanagh Street, Southbank,
Victoria 3006, Australia